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Background: One of the biggest obstacles to developing policies in cancer care in Southeast Asia is lack of reliable
data on disease burden and economic consequences. In 2012, we instigated a study of new cancer patients in the
Association of Southeast Asian Nations (ASEAN) region – the Asean CosTs In ONcology (ACTION) study – to assess
the economic impact of cancer.
Methods: The ACTION study is a prospective longitudinal study of 9,513 consecutively recruited adult patients with an
initial diagnosis of cancer. Twelve months after diagnosis, we recorded death and household financial catastrophe
(out-of-pocket medical costs exceeding 30 % of annual household income). We assessed the effect on these two
outcomes of a range of socio-demographic, clinical, and economic predictors using a multinomial regression model.
Results: The mean age of participants was 52 years; 64 % were women. A year after diagnosis, 29 % had died,
48 % experienced financial catastrophe, and just 23 % were alive with no financial catastrophe. The risk of dying
from cancer and facing catastrophic payments was associated with clinical variables, such as a more advanced
disease stage at diagnosis, and socioeconomic status pre-diagnosis. Participants in the low income category
within each country had significantly higher odds of financial catastrophe (odds ratio, 5.86; 95 % confidence
interval, 4.76–7.23) and death (5.52; 4.34–7.02) than participants with high income. Those without insurance were
also more likely to experience financial catastrophe (1.27; 1.05–1.52) and die (1.51; 1.21–1.88) than participants
with insurance.
Conclusions: A cancer diagnosis in Southeast Asia is potentially disastrous, with over 75 % of patients experiencing
death or financial catastrophe within one year. This study adds compelling evidence to the argument for policies that
improve access to care and provide adequate financial protection from the costs of illness.Background
The Association of Southeast Asian Nations (ASEAN)
region consists of ten countries – Brunei, Cambodia,
Indonesia, Laos, Malaysia, Myanmar, the Philippines,
Singapore, Thailand, and Vietnam – and is home to over
half a billion people. The burden of cancer is increasing
in the ASEAN region, due to population ageing and
growth and the adoption of cancer-associated lifestyle
behaviours [1]. In 2012, there were estimated to be overCorrespondence: mkimman@georgeinstitute.org.au
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to rise to 1.3 million per year by 2030 [2]. Survival rates
for most cancers are poor and quality of life is greatly
impaired [2–4]. In addition to this significant disease
burden, cancer can have a profound economic effect on
individuals and their households, especially among the
poor and under-insured [5].
Most studies examining the economic burden of cancer
have, however, been conducted in high-income settings.
Little is known about its economic impact in low- and
middle-income settings, where the financial implication of
a cancer diagnosis may not be equitable because out-of-
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treatment, but may include long-term costs of adjuvant
therapy and follow-up care [7–9]. Hence, a cancer diagno-
sis can quickly result in catastrophic payments for a
household; that is, spending a disproportionate amount of
household income on cancer treatment [10]. Furthermore,
patients may be unable to continue working due to the
burden of their symptoms, treatment, or side-effects, lead-
ing to poorer economic circumstances [11].
Health insurance is seen as an important means in of-
fering households protection from catastrophic pay-
ments for illness. However, the extent of financial
protection through insurance depends on which health
services are covered and the level of subsidy offered. In
the ASEAN region, while population coverage varies
between 8 % (Laos) and 100 % (Malaysia), all countries –
including those with universal health coverage – rely heav-
ily on OOP financing [12, 13].
Despite the risk of a cancer epidemic overwhelming
the region, governments have been slow to react to the
health consequences of socioeconomic and demographic
changes. Hence, in 2011, two regional initiatives were
launched to increase cancer awareness and inform priority
setting. First, a series of roundtable meetings of key stake-
holders and experts were organised to generate knowledge
and interest through engagement with the media [14, 15].
Second, a study of new cancer patients in eight countries
in the ASEAN region (Cambodia, Indonesia, Laos,
Malaysia, Myanmar, the Philippines, Thailand, and
Vietnam) was instigated – the Asean CosTs In ONcology
(ACTION) study – to assess the economic and health im-
pact of cancer. This paper presents the main results.
Methods
Ethical approval
The ACTION study was approved by the University of
Sydney’s Human Research Ethics Committee. Approvals
from local institutional ethics committees and other re-
gional or national regulatory bodies were obtained prior to
the initiation of the study in all centres (Additional file 1).
Written informed consent, complying with local, regional,
and national requirements, was obtained from all partici-
pants prior to entry into the study.
Study design
ACTION was a prospective longitudinal study; detailed
methods have been published previously [16]. In brief,
patients diagnosed with a first time cancer were con-
secutively recruited (within 12 weeks from initial date of
diagnosis) from 47 sites, including public and private
hospitals and cancer centres. Patients were aged 18 years
and older, aware of their cancer diagnosis, and willing to
participate in follow-up interviews. Participants were
interviewed (face-to-face or by telephone) at baseline, 3,and 12 months after diagnosis. Questionnaires were
translated into local languages.
Baseline measures and key outcomes
Data were collected on age, sex, marital status, country
of residence, highest level of education attained, employ-
ment status, recent experience of economic hardship
(whether in the previous 12 months they were unable to
make any necessary household payments (for example,
food, housing) or needed assistance to do so) [17], an-
nual household income, and health insurance status.
Clinical characteristics, cancer site, and cancer stage
(TNM classification) were obtained from medical re-
cords. Health-related quality of life was assessed using
the EuroQol (EQ-5D) [18]. Further details are given in
the study protocol [16].
The primary outcome at 12 months was financial ca-
tastrophe (FC) following treatment for cancer, defined as
OOP costs at 12 months equal to or exceeding 30 % of an-
nual household income [19, 20]. OOP costs represented
hospital and non-hospital health care costs which were
directly incurred by patients at point of delivery and not
reimbursed by insurance. Participants prospectively com-
pleted a cost diary for the duration of the study. The sec-
ond key outcome was all-cause mortality. FC and death
were recorded at both follow-up interviews.
Statistical analyses
Multinomial regression models were used to estimate
odds ratios (ORs) and 95 % confidence intervals (CIs)
for death and FC, relative to being alive without experi-
encing FC, thus allowing for death as a competing risk
to FC. Baseline characteristics considered for association
with these joint outcomes were socio-demographic (age,
sex, and level of education), economic (household in-
come grouped into low (0–75 % of mean national in-
come), middle (75–125 %), and high income (>125 %),
insurance status (yes or no), experience of economic
hardship, and paid work status), and clinical (baseline
health-related quality of life, cancer site – separately by
sex – and cancer stage) [21]. Due to small numbers for
some cancer sites, sites were grouped into body location
or system: digestive/gastrointestinal; breast; gynaeco-
logical; head and neck; haematological/blood; respira-
tory/thoracic; and other cancers. Analyses were adjusted
for age, sex, cancer stage, and geographic region,
grouped as low (Cambodia, Myanmar), low-middle
(Indonesia, Laos, Vietnam, the Philippines), and upper-
middle income (Thailand, Malaysia). Participants who
experienced FC at 3 months, but could not be contacted
at 12 months, were coded as having experienced FC at
12 months. Primary analyses were conducted on partici-
pants with complete data on outcome status at
12 months. More extreme cut-offs for household income
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mean national income); middle (50–150 %); and high in-
come (>150 %). Furthermore, multiple imputation (m= 5)
using predictive mean matching was carried out to impute
the missing data on the outcome variables. The imput-
ation models included the outcome variables themselves,
all socio-demographic, clinical, and economic predictors
examined, and country [22]. Analyses were performed
using STATA, version 12.0 (Stata, College Station, TX,
USA), and R, version 2.15.3 (R Foundation for Statistical
Computing, Vienna, Austria).
Results
Between March 2012 and September 2013, after exclu-
sions due to patient or doctor refusals, 9,513 patients
were recruited into the study. The mean age was
52 years, 64 % were women, 61 % had attained at least
secondary education, and 45 % had some form of health
insurance. The most common cancer site recorded was
breast (26 %); the greatest number was recruited in
Indonesia (Table 1). For patients with available data on
cancer stage (n = 5,159), 11 % presented with stage I,
31 % with stage II, 33 % with stage III, and 24 % with
stage IV cancers. Haematological cancers were diagnosed
in 825 patients (Additional file 2: Table S1).
The follow-up interviews at 3 and 12 months were com-
pleted by 7,245 (76 %) and 5,245 (55 %) participants, re-
spectively. At 12 months, 1,993 (29 %) participants had
died. Complete outcome data (data on FC and death) were
available for 6,787 participants (71 %) (Fig. 1).
Participants with incomplete outcome data (n = 2,726)
were slightly younger (51 versus 52 years), more likely to
be male (38 versus 33 %), and less likely to have a high
income (17 versus 38 %), compared to those with
complete outcome data (all P values <0.001). There were
no significant differences in other socio-demographic,
clinical, or economic characteristics.
At 12 months, 3,248 participants (48 % of those with
complete outcome data) experienced FC and 1,546
(23 %) were alive and did not experience FC. Survival
without FC was most frequent in participants with
haematological cancer (37 %), gynaecological cancer
(27 %), and breast cancer (26 %) (Fig. 2).
After controlling for confounding variables, women
had lower odds of death (OR, 0.62; 95 % CI, 0.51–0.75)
than men, but sex was not significantly associated with
FC, relative to the reference outcome (alive and no FC)
(Table 2). Age of >65 years was associated with a higher
odds of FC (1.51; 1.17–1.94) and death (2.64; 2.00–3.49),
compared to age <45 years. Being unmarried was also
associated with a higher odds of FC (1.09; 1.09–1.60)
and death (1.42; 1.15–1.77), compared to participants
who were married. Having completed primary education
only, compared to tertiary education, was significantlyassociated with a higher odds of FC (1.45; 1.16–1.82)
and death (2.50; 1.93–3.25).
Participants in the low income category within each
country had significantly higher odds of FC (5.86; 4.76–
7.23) and death (5.52; 4.34–7.02) than participants with
high income, relative to being alive and no FC. Using
more extreme cut-offs for low and high household in-
come (0–50 % of the mean national income for a low in-
come and >150 % for a high income) resulted in higher
odds of FC (9.16; 7.07–11.87) and death (9.30; 6.95–
12.44) for the low income category. The country-region
specific analysis showed that a low income is especially a
factor in predicting FC in the upper-middle income
countries (13.75; 10.21–18.51) and less so in lower-
middle income countries (1.97; 1.38–2.82) (Additional
file 2: Table S2a and S2b). Not having paid work also in-
creased the odds of FC (1.32; 1.11–1.56) and death (1.60;
1.31–1.94). Having some form of health insurance pro-
vided protection from FC; those without insurance were
more likely to experience FC than those with insurance
(1.27; 1.05–1.52). Participants without health insur-
ance were more likely to die (1.51; 1.21–1.88), relative
to being alive and not experiencing FC; health insur-
ance was inversely related to FC in upper-middle in-
come countries only.
Cancer stage IV at diagnosis was significantly associ-
ated with a higher odds of FC (1.52; 1.12–2.05) and
death (5.43; 3.76–7.82), compared to stage I. In terms of
health-related quality of life, a decrement of 0.1 point as
assessed on the EQ-5D was associated with higher odds
of FC (1.11; 1.07–1.16) and death (1.24; 1.18–1.30).
In females, cancer site was not associated with FC. In
males, cancer in the head and neck region (0.54; 0.36–
0.80) and haematological cancers (0.56; 0.42–0.76) were
associated with a lower odds of FC compared to digest-
ive cancers (reference group).
Sensitivity analyses employing missing value imput-
ation (Additional file 2: Table S3) did not change the in-
ferences, except that the effect of health insurance on
the odds of FC became non-significant at the conven-
tional 5 % level.Discussion
To our knowledge, the ACTION study is the largest ob-
servational study of the household burden of cancer yet
conducted in Asia. A year after diagnosis, almost a third
of patients affected by cancer in the ASEAN region died
and almost a half of their households faced catastrophic
health care expenses. Patients with advanced stages of
cancer at diagnosis and socioeconomically disadvantaged
cancer patients, including those with primary education
only, low income, and no health insurance, were more
likely to experience FC or die within 12 months.
Table 1 Demographic, socioeconomic, and clinical













Not married 2,154 23
Missing 7 <1
Level of education
0–6 years (primary) 3,693 39
7–12 years (secondary) 3,817 40
















Household income (of mean national income)
0–25 % 1,103 12
25–50 % 1,185 13
50–75 % 1,031 11
75–100 % 1,020 11
100–125 % 767 8
125–150 % 381 4
150–175 % 427 5
175–200 % 417 4
>200 % 1,819 19
Table 1 Demographic, socioeconomic, and clinical
characteristics of the study population (n = 9,513) (Continued)
Not known 1,336 14
Missing 27 <1
Main source of household income
Crops and agricultural sidelines 1,965 21
Family business 1,287 14
Wages 4,568 48
Remittances and gifts 455 5
Other income 1,213 13
Missing 25 <1
Health insurance status
Government-provided insurance 3,061 32
Employment-based insurance 568 6
Private insurance 857 9






Other (for example, military) 143 2










Mouth and pharynx 1,063 11
Oesophagus 160 2
Stomach 305 3
Colon and rectum 910 10
Liver 83 1
Pancreas 53 <1
Trachea, bronchus, and lung 623 7
Melanoma 40 <1
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able 1 Demographic, socioeconomic, and clinical
haracteristics of the study population (n = 9,513) (Continued)
Bladder 60 <1
Lymphomas and multiple myeloma 454 5
Leukaemia 371 4
Other malignant neoplasms 1,295 14
Missing 179 2
ancer stage
Stage I 590 6
Stage II 1,613 17
Stage III 1,696 18
Stage IV 1,260 13
None (haematological cancers) 825 9
Missing 3,529 37
Fig. 2 Competing outcomes of death, financial catastrophe, and
alive with no financial catastrophe at 12 months after diagnosis, by
location of cancer in the body
The ACTION Study Group BMC Medicine  (2015) 13:190 Page 5 of 11T
c
CThis research adds compelling evidence to the argu-
ment for effective cancer control policies and timely ac-
cess to affordable treatment in low- and middle-income
countries. Previously, evidence of significant household
economic burden due to cancer has come from only a
few, small cross-sectional studies [23, 24]. There has,
however, been increasing attention given to the eco-
nomic impact of non-communicable diseases in low-
and middle-income settings, with two recent reviewsFig. 1 Participant flowcharthighlighting the heavy financial burden that such dis-
eases pose on affected households [25, 26]. In a review
of studies that reported on expenditures on chronic dis-
eases, mean expenditures ranged from 5 % to 59 % of
household income, household total health expenditure,
and household non-food expenditure, but results on
catastrophic health expenditures were not reported [26].
A literature review on the costs imposed by non-
communicable diseases in low- and middle-income set-
tings included 19 studies that reported on OOP health
expenditure as a percentage of capacity to pay or total
household expenditure due to health shocks, and found
that between 0 % and 34 % of the study population expe-
rienced FC, depending on the methods used [25]. Com-
parison of these findings with our results is difficult due
to differences in defining catastrophic spending: some
studies used a threshold OOP share of total household
expenditure; others of household ‘capacity to pay’; or of
‘non-food expenditure’. In addition, the threshold used
also varies, ranging from 10 % to 40 %. Furthermore, in
the majority of the above-mentioned studies, OOP esti-
mates were based on retrospective recall of health care
utilisation in household surveys, while our study used a
prospective cost diary. Studies have shown that OOP esti-
mates depend heavily on the measures used and length of
recall periods [27, 28]. Compared to prospective cost diar-
ies, health care utilisation is generally under-reported in
household surveys [27]. Nonetheless, results from this
study, taken together with other studies, signal the poten-
tial for cancer to result in a significant economic burden.
Women were less likely to die in the year following a
cancer diagnosis than men, but no significant association
between the patient’s sex and their household’s odds of ex-
periencing FC was found. Better survival rates for female
cancers may be explained by the high proportion of breast
cancer in this population, and its relatively good progno-
sis, while colorectal, mouth and lung cancers, with a gen-
erally poor prognosis [29], were most common in men.
Table 2 Odds ratios (and 95 % confidence intervals) for financial catastrophe and death, relative to no financial catastrophe
(reference) in all participants with complete outcome data (n = 6,787), adjusted for age, sex, cancer stage, and geographic region
Characteristic Financial catastrophe Death
Age (years) <45 Reference Reference
45–54 1.05 (0.85–1.30) 1.08 (0.84–1.38)
55–64 1.41 (1.13–1.75) 1.59 (1.23–2.04)
≥65 1.51 (1.17–1.94) 2.64 (2.00–3.49)
Sex Men Reference Reference
Women 1.14 (0.96–1.36) 0.62 (0.51–0.75)
Highest level of education Tertiary Reference Reference
Secondary 1.44 (1.16–1.79) 1.43 (1.11–1.85)
Primary 1.45 (1.16–1.82) 2.50 (1.93–3.25)
Marital status Married Reference Reference
Unmarried 1.32 (1.09–1.60) 1.42 (1.15–1.77)
Health insurance Yes Reference Reference
No 1.27 (1.05–1.52) 1.51 (1.21–1.88)
Economic hardship No Reference Reference
Yes 1.40 (1.19–1.64) 1.82 (1.51–2.20)
Income level High Reference Reference
Middle 2.15 (1.73–2.67) 1.91 (1.47–2.47)
Low 5.86 (4.76–7.23) 5.52 (4.34–7.02)
Paid work Yes Reference Reference
No 1.32 (1.11–1.56) 1.60 (1.31–1.94)
Cancer region: females Digestive/gastrointestinal Reference Reference
Breast 0.99 (0.69–1.41) 0.45 (0.29–0.69)
Gynaecological 0.73 (0.49–1.08) 0.69 (0.43–1.11)
Head and neck 0.69 (0.40–1.19) 0.65 (0.35–1.18)
Haematological/blood 0.90 (0.69–1.19) 1.93 (1.39–2.69)
Respiratory/thoracic 1.36 (0.65–2.85) 2.28 (1.07–4.86)
Other 0.83 (0.48–1.41) 0.99 (0.54–1.83)
Cancer region: males Digestive/gastrointestinal Reference Reference
Head and neck 0.54 (0.36–0.80) 0.36 (0.24–0.55)
Haematological/blood 0.56 (0.42–0.76) 1.10 (0.80–1.51)
Respiratory/thoracic 1.18 (0.67–2.09) 1.88 (1.07–3.31)
Other 0.56 (0.37–0.86) 0.65 (0.41–1.01)
Cancer stage I Reference Reference
II 1.23 (0.94–1.60) 0.93 (0.65–1.34)
III 1.23 (0.94–1.62) 2.34 (1.65–3.33)
IV 1.52 (1.12–2.05) 5.43 (3.77–7.82)
None (haematological cancers) 0.68 (0.49–0.95) 3.04 (2.07–4.46)
EQ-5D score (per 0.1 decrement) 1.11 (1.07–1.16) 1.24 (1.18–1.30)
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creasing co-morbidities which result in greater com-
plexity of the illness and treatment. As expected, age
was significantly associated with the risk of death at12 months. A more advanced cancer stage at diagnosis
was associated with higher odds of FC and death.
We found that having a below average income, no health
insurance, not having paid work, having experienced
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rienced no more than primary education, were all
associated with a higher odds of experiencing FC.
Household income showed the strongest association,
with these patients having more than five times the
odds of FC when an income <75 % of the mean national
income was considered a low income, and even nine
times the odds when an income <50 % was used as the
threshold. That this gradient was found to be more
pronounced in upper-middle compared to lower-
middle income countries suggests that the risk of FC
posed by having a low income is as much based on rela-
tive as opposed to absolute disadvantage.
The relationship between health insurance and FC
found in the primary analyses of this study was not par-
ticularly strong, and was non-significant in the sensitivity
analysis where missing data were imputed. Analyses by
level of economic development provided some explan-
ation to these inconclusive results: in upper-middle in-
come countries (Malaysia and Thailand) health insurance
did provide significant protection from FC; but in lower-
middle income countries it did not. This may be explained
by the limitations of benefit packages available through
health insurance programs in some of the participating
lower-middle income countries, which has been well-
recognised as a problem in Vietnam and the Philippines
[13]. Since health insurance status was assessed as a cat-
egorical variable it was not possible to take into account
variations in level of coverage.
The findings in relation to the socioeconomic variables
reinforce the well-founded conclusions that can be
drawn from the social determinants literature – those at
greater levels of disadvantage tend to have higher risks
of financial hardship and poor health [30]. Reflecting this
was the strong relationship of various socioeconomic in-
dicators and death within 12 months. This, and the ob-
served association between low quality of life and higher
odds of FC, underscores the relationship between under-
lying economic disadvantage, health, and economic
outcomes in cancer.
The study has a number of limitations. We did not re-
cruit a random cross-section of people with incident
cancer in the region due to a variety of reasons. First, as
we could only identify cases once individuals presented
to hospital, we potentially excluded individuals who did
not seek hospital treatment due to geographical isola-
tion, poverty, or socio-cultural barriers [31]. Second, cli-
nicians responsible for enrolling patients into the study
appear to have under-recruited those with the most viru-
lent types of cancer, such as lung and liver cancers.
Third, public awareness of some types of cancer, specif-
ically breast cancer, was greater than for others, which is
likely to have additionally motivated certain cancer pa-
tients, particularly women, to agree to participate in thestudy. Furthermore, patients treated in private hospi-
tals were under-represented in the study (6 %) and it is
unclear whether this has introduced a bias in our esti-
mates of the level of FC. Although private hospitals
have often been observed to generate the highest OOP
expenses [25] they also tend to attract patients with a
higher income. All these factors compromise the gen-
eralisability of some of our results, and probably means
that we have underestimated the 12-month rate of
death from all cancers, but is unlikely to invalidate the
main conclusions. Another drawback is that 2,767 par-
ticipants (29 %) lacked at least one component of data
on death, household income, or OOP costs required to
compute the study outcomes. The challenges of elicit-
ing income and other socioeconomic data have been
well-documented [32], and incomplete follow-up due
to being unable to contact many subjects in rural areas,
despite repeated telephone calls and field visits, is inev-
itable in the region studied. The findings from the sen-
sitivity analysis, in which multiple imputation was used
to impute the missing data, did not vary substantially
from the non-imputed findings, and would not alter
conclusions.
These drawbacks have to be considered in the light of
the paucity of cancer statistics from the region sampled
[2, 15, 33]. The study benefited from having a large sam-
ple of patients with various cancer sites and cancer
stages from eight countries which have disparate health
systems. Due to the large size of the study, it was pos-
sible to produce reliable estimates of the influence of a
range of demographic, socioeconomic, and clinical pre-
dictors. In addition, the study’s longitudinal approach
improved on most previous economic studies which
used cross-sectional surveys based on retrospective
reporting of costs, as well as much smaller sample sizes,
with subsequent jeopardy for both bias and sampling
error. Furthermore, using a multinomial logistic regres-
sion model, we were able to adjust FC for the competing
outcome of death. This is important as studies that have
previously examined the burden to households associ-
ated with illnesses have generally focused exclusively on
‘economic’ outcomes in terms of OOP costs and FC [10,
25, 26], but have overlooked a crucial reason why pa-
tients may avoid, or not report incurring, high OOP
costs, that is, they may die, and this is unlikely to be
non-informative censoring.
Conclusions
This study provides the type of precise evidence that is
required to develop effective policies and programs to
address the overall burden of cancer care in the ASEAN
region, with potential generalisation elsewhere in the de-
veloping world. The results show that a cancer diagnosis
is disastrous, even within only 12 months, for over 75 %
The ACTION Study Group BMC Medicine  (2015) 13:190 Page 8 of 11of new patients. Socioeconomically disadvantaged cancer
patients and patients with advanced cancer stages at
diagnosis were common and particularly vulnerable to
adverse economic outcomes and poor survival. The need
for more resources to aid early detection as well as pol-
icies that improve access to care, by removing financial
barriers and providing adequate financial protection
from the costs of illness, is clear.
Key message
Over 75 % of new cancer patients in Southeast Asia ex-
perience financial catastrophe or die within one year. An
advanced stage at diagnosis and socioeconomic disad-
vantage are significant risk factors for these poor out-
comes. There is an urgent need for more resources to
aid early detection and policies aimed to provide ad-
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